MX2015012344A - 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin. - Google Patents

4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.

Info

Publication number
MX2015012344A
MX2015012344A MX2015012344A MX2015012344A MX2015012344A MX 2015012344 A MX2015012344 A MX 2015012344A MX 2015012344 A MX2015012344 A MX 2015012344A MX 2015012344 A MX2015012344 A MX 2015012344A MX 2015012344 A MX2015012344 A MX 2015012344A
Authority
MX
Mexico
Prior art keywords
dimethylcyclohex
hodgkin
pyran
pyridin
lymphoma
Prior art date
Application number
MX2015012344A
Other languages
English (en)
Inventor
Linda Snyder
Carl L Manthey
Boer Carla De
Yusri A Elsayed
Imran Khan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2015012344A publication Critical patent/MX2015012344A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se dirige a métodos para el tratamiento de linfoma de Hodgkin que comprende administrar a un paciente que lo necesite, una cantidad terapéuticamente eficaz de 4-ciano-N-(2-(4,4-dimetilciclohex-1-en-1-iI)-6-(2,2,6,6-tetrameti ltetrahidro-2H-piran-4-il)piridin-3-il)-1H-imidazola-2-carboxamid a, como monoterapia o como combinación o coterapia con uno o más agentes quimioterapéuticos o régimen de quimioterapia.
MX2015012344A 2013-03-15 2014-03-13 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin. MX2015012344A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792259P 2013-03-15 2013-03-15
PCT/US2014/025297 WO2014151253A1 (en) 2013-03-15 2014-03-13 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma

Publications (1)

Publication Number Publication Date
MX2015012344A true MX2015012344A (es) 2016-06-02

Family

ID=50625103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012344A MX2015012344A (es) 2013-03-15 2014-03-13 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.

Country Status (8)

Country Link
US (1) US20160015700A1 (es)
EP (1) EP2968289A1 (es)
JP (1) JP2016512836A (es)
CN (1) CN105283185A (es)
AU (1) AU2014235178A1 (es)
HK (1) HK1217918A1 (es)
MX (1) MX2015012344A (es)
WO (1) WO2014151253A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752980B (zh) 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
JP2023532866A (ja) * 2020-06-26 2023-08-01 デュレクト コーポレーション 自己免疫状態を処置するための酸素化コレステロールスルフェート類の使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز

Also Published As

Publication number Publication date
AU2014235178A1 (en) 2015-09-17
WO2014151253A1 (en) 2014-09-25
EP2968289A1 (en) 2016-01-20
HK1217918A1 (zh) 2017-01-27
CN105283185A (zh) 2016-01-27
US20160015700A1 (en) 2016-01-21
JP2016512836A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
HRP20181863T1 (hr) Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HK1217330A1 (zh) -苯基-氨甲酰衍生物及其作爲藥物用於治療乙型肝炎的用途
PH12015502549A1 (en) Heterocyclic derivatives
IN2015DN01156A (es)
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX364486B (es) Derivados de piridazinona-amidas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12015501038A1 (en) Inhibitors of iap
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MY179576A (en) Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
MX2015013740A (es) Derivados de pirazolnaftridinona, preparacion y uso terapautico de los mismos.
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2015012344A (es) 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HUE056121T2 (hu) Kompozíció UV-B terápia hatékonyságának növelésére, eljárás annak elõállítására, és alkalmazása